Canagliflozin: Improving diabetes by making urine sweet.

@article{Vouyiouklis2013CanagliflozinID,
  title={Canagliflozin: Improving diabetes by making urine sweet.},
  author={Mary Vouyiouklis},
  journal={Cleveland Clinic journal of medicine},
  year={2013},
  volume={80 11},
  pages={683-7}
}
Canagliflozin is the first sodium-glucose cotransport 2 (SGLT2) inhibitor approved in the United States for treating type 2 diabetes mellitus. This drug blocks reabsorption of glucose in the proximal tubule, lowering the renal threshold for glucose and thereby increasing glucose excretion. Its novel mechanism of action is insulin-independent. Trials have demonstrated reductions in fasting glucose and hemoglobin A1c levels, with the added benefit of weight loss. The adverse effects most often… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.

Similar Papers

Loading similar papers…